Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.38 |
| ▸ | ABAT | P80404 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245711 | 0.86 | CYP2A6 (0.44) | CYP2A6KDM4ERAB9APTGS2KIF11 | |
| SCHEMBL2361718 | 0.79 | CYP2A6 (0.44) | CYP2A6KDM4ERAB9APTGS2KIF11 | |
| SCHEMBL4742869 | 0.79 | ALDH1A1 (0.48) | CYP2A6KIF11ALDH1A1TDP1BRD4 | |
| SCHEMBL889055 | 0.79 | CYP2A6 (0.44) | CYP2A6KDM4ERAB9AKIF11ALDH1A1 | |
| SCHEMBL19364798 | 0.79 | CYP2A6 (0.44) | CYP2A6KDM4ERAB9APTGS2KIF11 | |
| SCHEMBL29957251 | 0.79 | CYP2A6 (0.44) | CYP2A6KDM4ERAB9APTGS2KIF11 | |
| SCHEMBL7649873 | 0.78 | TDP1 (0.47) | CYP2A6KDM4ERAB9APTGS2KIF11 | |
| SCHEMBL7653937 | 0.75 | NPSR1 (0.53) | CYP2A6KDM4EKIF11ALDH1A1TDP1 | |
| SCHEMBL18745936 | 0.75 | CCNE2 (0.34) | RAB9AALDH1A1MEN1NPC1MAPT | |
| SCHEMBL17919527 | 0.75 | ALDH1A1 (0.43) | CYP2A6KDM4EKIF11ALDH5A1ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6399642-B2 | TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-06-04 | — | — | US | disclosed |
| US-6310076-B1 | TREATING BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, TREATING DISEASES MEDIATED BY ALPHA-1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2001-07-26 | — | — | US | disclosed |
| US-6221892-B1 | Heterocyclic topoisomerase poisons | THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS | 2001-04-24 | — | — | US | disclosed |
| US-6211198-B1 | BENIGN PROSTATE HYPERPLASIA; INTRAOCULAR PRESSURE; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-1054870-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6063801-A | Heterocyclic topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999041241-A1 | HETEROCYCLIC TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | CYP2A6 482/4885KDM4E 2785/4885RAB9A 3293/4885 |
| US-20010009919-A1 | Heterocyclic topoisomerase poisons | TOP1, TOP2A, TOP2B | CYP2A6 1329/4885KDM4E 2275/4885RAB9A 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.